CRISPR gene editing can cause hundreds of unintended mutations
As CRISPR-Cas9 starts to move into clinical trials, a new study has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome.
List view / Grid view
As CRISPR-Cas9 starts to move into clinical trials, a new study has found that the gene-editing technology can introduce hundreds of unintended mutations into the genome.
Licensing agreement will expand Oxford Genetics growing bio-therapeutic discovery, design and development service business.
Scientists have created an innovative technique for studying how chlamydia interacts with the human immune system...
Using state-of-the-art gene editing technology, scientists have discovered a promising target to treat atypical teratoid/rhabdoid tumour (AT/RT) - a highly aggressive and therapy resistant brain tumour that mostly occurs in infants.
Neonatal diabetes mellitus (NDM), or diabetes among infants less than six months of age, is a rare form of diabetes caused by a mutation in genes crusial to the development or function of beta cells. In about half of such cases, the disease becomes permanent (PNDM). Mutations in more than…
Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model...
10 February 2017 | By Charles River
In this webinar, Charles River discuss the utilisation of CRISPR/Cas9 technology in drug discovery, with an emphasis on generation of in vitro models for high-throughput screening, and creating new mouse models...
2 December 2016 | By Niamh Louise Marriott, Digital Editor
These systems will allow researchers worldwide to rapidly and accurately explore the changing role of genes as the cells develop into tissues...
2 December 2016 | By Charles Rivers Laboratories
Charles River Laboratories has launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology...
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers from the Wellcome Trust have adapted a CRISPR gene editing technique and used it to find new therapeutic targets for acute myeloid leukaemia...
29 September 2016 | By Intellicyt
This webinar highlights the use of the iQue Screener for high-throughput screening of stem cells, small molecules and CRISPR functional screening, presented by David Sykes, M.D., Ph.D., Researcher from Massachusetts General Hospital and Thibault Jonckheere, CEO and Séverine Giltaire, Senior Scientist from ImmunXperts...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CRISPR/Cas9 is likely one of the most revolutionary tools in biotechnology, with tremendous implications for a broad range of biological and medical disciplines. As programmable scissors this technology allows cleavage of DNA at predefined sites in the genome of cells...
15 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Foetal haemoglobin lacks beta sub-units and has gamma sub-units instead. Thus, beta-thalassemia or SCD–associated mutations, which impair the production or function of the beta sub-unit, do not cause problems with foetal haemoglobin, which can transport oxygen effectively in adults...
14 July 2016 | By Victoria White, Digital Content Producer
The Scripps Research Institute scientists behind the study say their findings may bring doctors closer to using gene therapies to grow and repair tendons...